Structure−activity relationships in a series of (2-oxo-1,4-benzodiazepin-3-yl)-succinamides identified highly potent inhibitors of γ-secretase mediated signaling of Notch1/2/3/4 receptors. On the basis of its robust in vivo efficacy at tolerated doses in Notch driven leukemia and solid tumor xenograft models, 12 (BMS-906024) was selected as a candidate for clinical evaluation.
Inhibition of the bromodomain and
extra-terminal (BET) family of
adaptor proteins is an attractive strategy for targeting transcriptional
regulation of key oncogenes, such as c-MYC. Starting with the screening
hit 1, a combination of structure–activity relationship
and protein structure-guided drug design led to the discovery of a
differently oriented carbazole 9 with favorable binding
to the tryptophan, proline, and phenylalanine (WPF) shelf conserved
in the BET family. Identification of an additional lipophilic pocket
and functional group optimization to optimize pharmacokinetic (PK)
properties culminated in the discovery of 18 (BMS-986158)
with excellent potency in binding and functional assays. On the basis
of its favorable PK profile and robust in vivo activity in a panel
of hematologic and solid tumor models, BMS-986158 was selected as
a candidate for clinical evaluation.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.